Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastos-Oreiro, Mariana, Gutierrez, Antonio, Reguera, Juan Luís, Iacoboni, Gloria, López-Corral, Lucía, Terol, María José, Ortíz-Maldonado, Valentín, Sanz, Jaime, Guerra-Dominguez, Luisa, Bailen, Rebeca, Mussetti, Alberto, Abrisqueta, Pau, Hernani, Rafael, Luzardo, Hugo, Sancho, Juan-Manuel, Delgado-Serrano, Javier, Salar, Antonio, Grande, Carlos, Bento, Leyre, González de Villambrosía, Sonia, García-Belmonte, Daniel, Sureda, Anna, Pérez-Martínez, Antonio, Barba, Pere, Kwon, Mi, Martín García-Sancho, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336530/
https://www.ncbi.nlm.nih.gov/pubmed/35911769
http://dx.doi.org/10.3389/fimmu.2022.855730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336530/
https://www.ncbi.nlm.nih.gov/pubmed/35911769
http://dx.doi.org/10.3389/fimmu.2022.855730

Ejemplares similares